STOCK TITAN

MALLINCKRODT PB LTD CO - MCKPF STOCK NEWS

Welcome to our dedicated page for MALLINCKRODT PB CO news (Ticker: mckpf), a resource for investors and traders seeking the latest updates and insights on MALLINCKRODT PB CO stock.

Mallinckrodt PB Ltd Co, also known as MCKPF, is a global specialty pharmaceutical company focused on developing, manufacturing, and distributing specialty pharmaceutical products and therapies. They operate in the areas of autoimmune and rare diseases, neurology, rheumatology, hepatology, and more. Mallinckrodt recently announced FDA approval for their Acthar® Gel Single-Dose Pre-filled SelfJect™ Injector, a new delivery device designed to help patients with chronic and acute inflammatory and autoimmune conditions administer Acthar Gel subcutaneously. With a track record spanning over 70 years and a commitment to patients, Mallinckrodt continues to provide innovative therapies and support programs.

Rhea-AI Summary
Mallinckrodt plc reports strong financial results for fiscal year 2023, exceeding high-end guidance on net sales and adjusted EBITDA. Key milestones achieved in Specialty Brands with successful product launches and FDA approvals. New board members appointed. Financial guidance for 2024 provided. Detailed analysis of positive and negative aspects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Mallinckrodt plc announces positive findings from a retrospective analysis on Acthar Gel treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis. The study indicates similar health status improvement and symptom reduction in both groups, suggesting Acthar Gel as a viable treatment option for sarcoidosis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Mallinckrodt plc appoints Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands. Mr. O'Neill brings over 25 years of experience in manufacturing operations and will lead key initiatives to enhance supply performance and launch new products. Mallinckrodt aims for long-term growth under his leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Mallinckrodt plc receives FDA approval for Acthar Gel Single-Dose Pre-filled SelfJect Injector, a new delivery device for patients with inflammatory and autoimmune conditions. The device aims to simplify Acthar Gel administration, enhancing patient control. The product is set to launch in the U.S. in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is Mallinckrodt PB Ltd Co focused on?

Mallinckrodt PB Ltd Co is focused on developing, manufacturing, and distributing specialty pharmaceutical products and therapies.

What recent achievement did Mallinckrodt have?

Mallinckrodt recently announced FDA approval for their Acthar® Gel Single-Dose Pre-filled SelfJect™ Injector, a new delivery device designed for patients with chronic and acute inflammatory and autoimmune conditions.

What areas does Mallinckrodt operate in?

Mallinckrodt operates in the areas of autoimmune and rare diseases, neurology, rheumatology, hepatology, and more.

What support programs does Mallinckrodt offer?

Mallinckrodt offers a suite of services for eligible patients, including support with insurance coverage, commercial copay assistance, a patient assistance program, injection training services, and customized assistance by a nurse navigator.
MALLINCKRODT PB LTD CO

NYSE:MCKPF

MCKPF Rankings

MCKPF Stock Data

10.30M
13.46%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Dublin